Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis

OBJECTIVE: The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic brea...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMJ Open
Autori principali: Huang, Xiaoting, Weng, Xiuhua, Lin, Shen, Liu, Yiwei, Luo, Shaohong, Wang, Hang, Ming, Wai-kit, Huang, Pinfang
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2020
Soggetti:
Health Economics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7462248/
https://ncbi.nlm.nih.gov/pubmed/32868353
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-036107
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi